Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 218-231, September 2005

Genetic Changes in Ovarian Cancer

  • Fu-Shing Liu

      Affiliations

    • Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr. Fu-Shing Liu, Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, 160, Section 3, Chung-Kang Road, Taichung, Taiwan

Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan

Received 11 July 2005; received in revised form 13 July 2005; accepted 14 July 2005.

Article Outline

Summary

Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Chemoresistance may be multifactorial and related to multiple mechanisms, such as alterations in drug transport, changes in cellular proteins involved in detoxification, altered drug target, changes in DNA repair mechanisms, increases in drug damage tolerance, and genetic changes. Genetic changes appear to be associated directly with the loss of chemosensitivity in ovarian cancer. In this review, we detail the possible genetic changes that occur in ovarian cancer, including activation of specific oncogenes, inactivation of tumor suppressor genes, and downregulation of metastasis suppressor genes.

Key Words:  metastasis suppressor gene , oncogene , ovarian cancer , tumor suppressor gene

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Ozols R . Treatment of gynecologic cancer: the US experience . Tumori . 1999;85:S5–11
  2. Pierotti NA , Schichman SA , Sozzi G , Croce CM . Oncogenes . In:  Bast RC ,  Kufe DW ,  Pollock RE ,  Weischselbaum RR ,  Holland JF ,  Frei E editor. Cancer Medicine . Ontario: BC Decker Inc; 2000;p. 56–66
  3. Liu J , Yang G , Thompson-Lanza JA , et al.   A genetically defined model for human ovarian cancer . Cancer Res . 2004;64:1655–1663
  4. Barbacid M . Ras genes . Annu Rev Biochem . 1987;56:779–827
  5. Fabjani G , Kriegshaeuser G , Schuetz A , Prix L , Zeillinger R . Biochip for K-ras mutation screening in ovarian cancer . Clin Chem . 2005;51:784–787
  6. Almoguera C , Shibata D , Forrester K , Martin J , Arnheim N , Perucho M . Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes . Cell . 1988;53:549–554
  7. Bos JL , Fearon ER , Hamilton SR , et al.   Prevalence of ras gene mutations in human colorectal cancers . Nature . 1987;327:293–297
  8. Forrester K , Almoguera C , Han K , Grizzle WE , Perucho M . Detection of high incidence of K-ras oncogenes during human colon tumorigenesis . Nature . 1987;327:298–303
  9. Visvanathan KV , Pocock RD , Summerhayes IC . Preferential and novel activation of H-ras in human bladder carcinomas . Oncogene Res . 1988;3:77–86
  10. Bos JL , Verlaan-de Vries M , van der Eb AJ , et al.   Mutations in N-ras predominate in acute myeloid leukemia . Blood . 1987;69:1237–1241
  11. Bian D , Su S , Mahanivong C , et al.   Lysophosphatidic acid stimulates ovarian cancer cell migration via a ras-MEK kinase 1 pathway . Cancer Res . 2004;64:4209–4217
  12. Bell DA . Origins and molecular pathology of ovarian cancer . Mod Pathol . 2005;18:S19–S32
  13. Hogdall EV , Hogdall CK , Blaakaer J , et al.   K-ras alterations in Danish ovarian tumour patients. From the Danish “Malova” ovarian cancer study . Gynecol Oncol . 2003;89:31–36
  14. Singer G , Oldt R , Cohen Y , et al.   Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma . J Natl Cancer Inst . 2003;95:484–486
  15. Singer G , Kurman RJ , Chang H-W , et al.   Diverse tumorigenic pathways in ovarian serous carcinoma . Am J Pathol . 2002;160:1223–1228
  16. Pohl G , Ho CL , Kurman RJ , Bristow R , Wang TL , Shih IeM . Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations . Cancer Res . 2005;65:1994–2000
  17. Hsu CY , Bristow R , Cha MS , et al.   Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas . Clin Cancer Res . 2004;10:6432–6436
  18. Jamieson S , Alexiadis M , Fuller PJ . Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors . Gynecol Oncol . 2004;95:603–609
  19. Otsuka J , Okuda T , Sekizawa A , et al.   K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma . Med Electron Microsc . 2004;37:188–192
  20. Manavi M , Bauer M , Baghestanian M , et al.   Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium . Tumour Biol . 2001;22:299–309
  21. Amemiya S , Sekizawa A , Otsuka J , Tachikawa T , Saito H , Okai T . Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability . Int J Gynaecol Obstet . 2004;86:371–376
  22. Yang G , Thompson JA , Fang B , Liu J . Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer . Oncogene . 2003;22:5694–5701
  23. Reese DM , Slamon DJ . HER-2/neu signal transduction in human breast and ovarian cancer . Stem Cells . 1997;15:1–8
  24. Shih C , Padhy LC , Murray M , Weinberg RA . Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts . Nature . 1981;290:261–262
  25. Slamon DJ , Godolphin W , Jones LA , et al.   Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer . Science . 1989;244:707–712
  26. Afifi AM , Werness BA , Mark HFL . HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma . Exp Mol Pathol . 1999;66:165–169
  27. Hengstler JG , Lange J , Kett A , Dornhofer N , et al.   Contribution of c-erbB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer . Cancer Res . 1999;59:3206–3214
  28. Meden H , Marx D , Roegglen T , Schauer A , Kuhn W . Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer . Int J Gynecol Pathol . 1998;17:61–65
  29. Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F, Knapstein PG, et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma . Gynecol Oncol . 1996;62:268–277
  30. Meden H , Kuhn W . Overexpression of the oncogene c-erbB- 2 (HER2/neu) in ovarian cancer: a new prognostic factor . Eur J Obstet Gynecol Reprod Biol . 1997;71:173–179
  31. Pegram MD , Finn RS , Arzoo K , Beryt M , Pietras RJ , Slamon DJ . The effect of HER-2/neu overexpression on chemo-therapeutic drug sensitivity in human breast and ovarian cancer cells . Oncogene . 1997;15:537–547
  32. Tsai TC, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, et al. Enhanced chemoresistance by elevation of p185neu level in HER2/neu-transfected human lung cancer cells . J Natl Cancer Inst . 1995;87:682–684
  33. Yu D , Liu B , Tan M , Li J , Wang SS , Hung MC . Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms . Oncogene . 1996;13:1359–1365
  34. Riener EK , Amold N , Kommoss F , Lauinger S , Pfisterer J . The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study . Gynecol Oncol . 2004;95:89–94
  35. Mancini A , Koch A , Wilms R , Tamura T . c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms . J Biol Chem . 2002;277:14635–14640
  36. Roussel MF , Downing JR , Rettenmier CW , Sherr CJ . A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential . Cell . 1988;55:979–988
  37. Woolford J , McAuliffe A , Rohrschneider LR . Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype . Cell . 1988;55:965–977
  38. Suzuki M , Sekiguchi I , Ohwada M , et al.   Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation . Oncology . 1996;53:99–103
  39. Yokoyama Y , Morishita S , Takahashi Y , Hashimoto M , Tamaya T . Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme . Br J Cancer . 1997;76:977–982
  40. Wu R , Lin L , Beer DG , et al.   Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas . Am J Pathol . 2003;162:1603–1610
  41. Galmozzi E , Casalini P , Iorio MV , Casati B , Olgiati C , Menard S . HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA . J Cell Physiol . 2004;200:82–88
  42. Casalini P , Botta L , Menard S . Role of p53 in HER2-induced proliferation or apoptosis . J Biol Chem . 2001;276:12449–12453
  43. Tashiro H , Miyazaki K , Okamura H , Iwai A , Fukumoto M . c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression . Int J Cancer . 1992;50:828–833
  44. Iba T , Kigawa J , Kanamori Y , et al.   Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer . Cancer Sci . 2004;95:418–423
  45. Presneau N , Manderson EN , Tonin PN . The quest for a tumor suppressor gene phenotype . Curr Mol Med . 2003;3:605–629
  46. Paige AJ . Redefining tumour suppressor genes: exceptions to the two-hit hypothesis . Cell Mol Life Sci . 2003;60:2147–2163
  47. Feki A , Irminger-Finger I . Mutational spectrum of p53 mutations in primary breast and ovarian tumors . Crit Rev Oncol Hematol . 2004;52:103–116
  48. Greenblatt MS , Bennett WP , Hollstein M , Harris CC . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res . 1994;54:4855–4878
  49. Beroud C , Soussi T . p53 gene mutation: software and database . Nucl Acids Res . 1998;26:200–204
  50. Casey G , Lopez ME , Ramos JC , et al.   DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies . Oncogene . 1996;13:1971–1981
  51. Ceccaroni M , Chieco P , Alboni C , et al.   p53 expression, DNA ploidy and mitotic index as prognostic factors in patients with epithelial ovarian carcinoma . Tumori . 2004;90:600–606
  52. Singer G , Stohr R , Cope L , et al.   Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation . Am J Surg Pathol . 2005;29:218–224
  53. Ho ES , Lai CR , Hsieh YT , et al.   p53 mutation is infrequent in clear cell carcinoma of the ovary . Gynecol Oncol . 2001;80:189–193
  54. Kohler MF , Kerns BJ , Humphrey PA , Marks JR , Bast RC , Berchuck A . Mutation and overexpression of p53 in early-stage epithelial ovarian cancer . Obstet Gynecol . 1993;81:643–650
  55. Marks JR , Davidoff AM , Kerns BJ , et al.   Overexpression and mutation of p53 in epithelial ovarian cancer . Cancer Res . 1991;51:2979–2984
  56. Reles A , Wen WH , Schmider A , et al.   Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer . Clin Cancer Res . 2001;7:2984–2997
  57. Johnstone RW , Ruefli AA , Lowe SW . Apoptosis: a link between cancer genetics and chemotherapy . Cell . 2002;108:153–164
  58. Kigawa J , Sato S , Shimada M , et al.   p53 gene status and chemosensitivity in ovarian cancer . Hum Cell . 2001;14:165–171
  59. Buttitta F , Marchetti A , Gadducci A , et al.   p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study . Br J Cancer . 1997;75:230–235
  60. Righetti SC , Della Torre G , Pilotti S , et al.   A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma . Cancer Res . 1996;56:689–693
  61. Bergh J , Norberg T , Sjogren S , Lindgren A , Holmberg L . Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy . Nat Med . 1995;1:1029–1034
  62. Di Leo A , Bajetta E , Biganzoli L , et al.   An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis . Eur J Cancer . 1995;31:2248–2254
  63. Jacquemier J , Penault-Llorca F , Viens P , et al.   Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression . Anticancer Res . 1994;14:2773–2778
  64. Smith-Sorensen B , Kaern J , Holm R , Dorum A , Trope C , Borresen-Dale AL . Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status . Br J Cancer . 1998;78:375–381
  65. Yazlovitskaya EM , DeHaan RD , Persons DL . Prolonged wild-type p53 protein accumulation and cisplatin resistance . Biochem Biophys Res Commun . 2001;283:732–737
  66. Li L , Luan Y , Wang G , et al.   Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma . Int J Mol Med . 2004;14:257–264
  67. Kozubik A , Horvath V , Svihalkova-Sindlerova L , et al.   High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro . Biochem Pharmacol . 2005;69:373–383
  68. Fraser M , Leung BM , Yan X , Dan HC , Cheng JQ , Tsang BK . p53 is a determinant of Xiap/Akt-mediated chemoresistance in human ovarian cancer cells . Cancer Res . 2003;63:7081–7088
  69. Risch HA , McLaughlin JR , Cole DEC , et al.   Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer . Am J Hum Genet . 2001;68:700–710
  70. Cass I , Baldwin RL , Varkey T , Moslehi R , Narod SA , Karlan BY . Improved survival in women with BRCA-associated ovarian carcinoma . Cancer . 2003;97:2187–2195
  71. Robles-Diaz L , Goldfrank DJ , Kauff ND , Robson M , Offit K . Hereditary ovarian cancer in Ashkenazi Jews . Fam Cancer . 2004;3:259–264
  72. Hartman AR , Ford JM . BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair . Nat Genet . 2002;32:180–184
  73. Yang H , Jeffrey PD , Miller J , et al.   BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure . Science . 2002;297:1837–1848
  74. Xu X , Weaver Z , Linke SP , et al.   Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells . Mol Cell . 1999;3:389–395
  75. Thompson ME , Jensen RA , Obermiller PS , Page DL , Holt JT . Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression . Nat Genet . 1995;9:444–450
  76. Hakem R , de la Pompa JL , Sirard C , et al.   The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse . Cell . 1996;85:1009–1023
  77. Boyd J , Sonoda Y , Federici MG , et al.   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer . JAMA . 2000;283:2260–2265
  78. Ben David Y , Chetrit A , Hirsh-Yechezkel G , et al.   Effect of BRCA mutations on the length of survival in epithelial ovarian tumors . J Clin Oncol . 2002;20:463–466
  79. Rubin SC , Benjamin I , Behbakht K , et al.   Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1 . N Engl J Med . 1996;335:1413–1416
  80. Aida H , Takakuwa K , Nagata H , et al.   Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 . Clin Cancer Res . 1998;4:235–240
  81. Johannsson OT , Ranstam J , Borg A , Olsson H . Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden . J Clin Oncol . 1998;16:397–404
  82. Pharoah PD , Easton DF , Stockton DL , Gayther S , Ponder BA . Survival in familial, BRCA1-associated, and BRCA2- associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group . Cancer Res . 1999;59:868–871
  83. Rhei E , Bogomolniy F , Federici MG , et al.   Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers . Cancer Res . 1998;58:3193–3196
  84. Cvetkovic D , Pisarcik D , Lee C , Hamilton TC , Abdollahi A . Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer . Gynecol Oncol . 2004;95:449–455
  85. Noviello C , Courjal F , Theillet C . Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion . Clin Cancer Res . 1996;2:1601–1606
  86. Li Z , Meng Z , Sayeed A , Shalaby R , Ljung B , Dairkee S . Genome-wide allelotyping of a new in vitro model system reveals early events in breast cancer progression . Cancer Res . 2002;62:5980–5987
  87. Tibiletti M , Bernasconi B , Furlan D , et al.   Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms . Clin Cancer Res . 2001;7:3404–3409
  88. Abdollahi A , Godwin A , Miller P , et al.   Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells . Cancer Res . 1997;57:2029–2034
  89. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J, et al. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain . EMBO J . 1997;16:2814–2825
  90. Kas K , Voz ML , Hensen K , Meyen E , Van de Ven W . Transcriptional activation capacity of the novel PLAG family of zinc finger proteins . J Biol Chem . 1998;273:23026–23032
  91. Abdollahi A , Roberts D , Godwin A , et al.   Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors . Oncogene . 1997;14:1973–1979
  92. Abdollahi A , Bao R , Hamilton TC . LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein . Oncogene . 1999;18:6477–6487
  93. Abdollahi A , Pisarcik D , Roberts D , Weinstein J , Cairns P , Hamilton TC . LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24–25, is epigenetically regulated in cancer . J Biol Chem . 2003;278:6041–6049
  94. Shridhar V , Bible KC , Staub J , et al.   Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer . Cancer Res . 2001;61:4258–4265
  95. Strathdee G , Davies BR , Vass JK , Siddiqui N , Brown R . Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene . Carcinogenesis . 2004;25:693–701
  96. Kauffman EC , Robinson VL , Stadler WM , Sokoloff MH , Rinker-Schaeffer CW . Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site . J Urol . 2003;169:1122–1133
  97. Yoshida BA , Sokoloff MM , Welch DR , Rinker-Schaeffer CW . Metastasis-suppressor genes: a review and perspective on an emerging field . J Natl Cancer Inst . 2001;92:1717–1730
  98. Ichikawa T , Ichikawa Y , Isaacs JT . Genetic factors and suppression of metastatic ability of prostatic cancer . Cancer Res . 1991;51:3788–3792
  99. Ichikawa T , Ichikawa Y , Dong J , et al.   Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11 . Cancer Res . 1992;52:3486–3490
  100. Dong JT , Lamb PW , Rinker-Schaeffer CW , et al.   KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 . Science . 1995;268:884–886
  101. White A , Lamb PW , Barrett JC . Frequent downregulation of the KAI1 (CD82) metastasis suppressor protein in human cancer cell lines . Oncogene . 1998;16:3143–3149
  102. Dong JT , Suzuki H , Pin SS , et al.   Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss . Cancer Res . 1996;56:4387–4390
  103. Ueda T , Ichikawa T , Tamaru J , et al.   Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer . Am J Pathol . 1996;149:1435–1440
  104. Houle CD , Ding XY , Foley JF , Afshari CA , Barrett JC , Davis BJ . Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression . Gynecol Oncol . 2002;86:69–78
  105. Liu FS , Dong JT , Chen JT , Hsieh YT , Ho ES , Hung MJ . Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma . Gynecol Oncol . 2000;78:10–15
  106. Viel A , Dall'Agnese L , Canzonieri V , et al.   Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis . Cancer Res . 1995;55:2645–2650
  107. Hennessy C , Henry JA , May FEB , et al.   Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis . J Natl Cancer Inst . 1991;83:281–285
  108. Royds JA , Cross SS , Silcocks PB , et al.   Nm23 “anti-metastatic” gene product expression in colorectal carcinoma . J Pathol . 1994;172:261–266
  109. Florenes VA , Aamdal S , Myklebost O , et al.   Level of nm23 messenger RNA in metastatic malignant melanoma: inverse correlation to disease progression . Cancer Res . 1992;52:6088–6091
  110. Luo W , Matsuo K , Nagayma Y , et al.   Immunohistochemical analysis of expression of nm23H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis . Thyroid . 1994;3:105–109
  111. Higashiyama M , Doi O , Yokouchi H , et al.   Immunohisto-chemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value . Br J Cancer . 1992;66:533–536
  112. Scambia G , Ferrandina G , Marone M , et al.   Nm23 in ovarian cancer: correlation with clinical outcome and other clinico-pathological and biochemical prognostic parameters . J Clin Oncol . 1996;14:334–342
  113. Harlozinska A , Bar JK , Gerber J . Nm23 expression in tissue sections and tumor effusion cells of ovarian neoplasms . Int J Cancer . 1996;69:415–419
  114. Schneider J , Romero H , Ruiz R , et al.   Nm23 expression in advanced and borderline ovarian carcinoma . Anticancer Res . 1996;16:1197–1202
  115. Tas F, Tuzlali S, Aydiner A, Saip P, Salihoglu Y, Iplikci A, et al. Prognostic role of nm23 gene expression in patients with ovarian cancer . Am J Clin Oncol . 2002;25:164–167
  116. Cuenda A . Mitogen-activated protein kinase kinase 4 (MKK4) . Int J Biochem Cell Biol . 2000;32:581–587
  117. Yoshida BA , Dubauskas Z , Chekmareva MA , Christiano TR , Stadler WM , Rinker-Schaeffer CW . Mitogen-activated protein kinase kinase 4/stress activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17 . Cancer Res . 1999;59:5483–5487
  118. Kim HL , Vander Griend DJ , Yang X , et al.   Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers . Cancer Res . 2001;61:2833–2837
  119. Yamada SD , Hickson JA , Hrobowski Y , et al.   Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma . Cancer Res . 2002;62:6717–6723

PII: S1028-4559(09)60144-3

doi:10.1016/S1028-4559(09)60144-3

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 218-231, September 2005

Article Tools